Business Context and Reporting Period
This Form 8-K is filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on August 1, 2019. The filing serves to announce the company's financial results for the quarter ended June 30, 2019. The registrant is incorporated in Delaware and trades on the Nasdaq under the symbol CBIO.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only indicates that the company issued a press release announcing its second-quarter 2019 operating and financial results.
Guidance, Outlook, and Risks
The filing references a corporate update and financial results in the attached press release (Exhibit 99.1) but does not explicitly state guidance, outlook, management commentary, risks, or contingencies within the body of this 8-K document. The information in Item 2.02 is explicitly stated as not being "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash position figures in the attached Exhibit 99.1 press release.
- Confirm the company name is Catalyst Biosciences, Inc. (CBIO), as the metadata reference to "Gyre Therapeutics" appears to be incorrect based on the filing content.
- Review the "Corporate Update" section of the press release for any new clinical trial data or partnership announcements not detailed in this summary.
- Check the company's cash runway and burn rate as disclosed in the full financial statements referenced in the press release.